CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
整合最新证据与专家观点于多发性骨髓瘤管理：2025 Bridging the Gaps 会议共识建议
英文原题：Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
查看英文原题
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）治疗选择的迅速扩展，使最佳治疗顺序和临床应用方面产生了不确定性。为弥补证据缺口，2025年Bridging the Gaps共识会议召集了16位美国MM专家，他们审查了数据、就争议问题进行辩论，并对采用改良Delphi方法制定的51个问题进行了投票。最终形成了11项共识推荐，涵盖冒烟型MM、一线治疗、移植、维持治疗以及复发/难治性疾病。关键主题包括整合四联诱导治疗、个体化维持治疗以及早期转诊接受CAR-T 治疗。这些基于专家意见的推荐提供了实用指导，同时突出了需要进一步研究的领域。
展开英文摘要原文
The rapid expansion of therapeutic options for multiple myeloma (MM) has created uncertainty regarding optimal sequencing and clinical application. To address gaps in evidence, the 2025 Bridging the Gaps Consensus Conference convened 16 US MM experts who reviewed data, debated controversies, and voted on 51 questions that were developed using a modified Delphi approach.
Eleven consensus recommendations were developed spanning smoldering MM, frontline therapy, transplant, maintenance, and relapsed/refractory disease. Key themes included integration of quadruplet induction, individualized maintenance, and early referral for CAR-T therapy. These expert-derived recommendations provide practical guidance while highlighting areas requiring further investigation.
论文信息
- 作者
- Chari A、Costello C、Krishnan A、Patel K、Banerjee R、Berdeja JG、Biran N、Callander N
- 第一作者单位
- Division of Hematology/Oncology, University of California San Francisco, San Francisco, California, USA.United States
- 通讯作者单位
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.United States
- 文献类型
- 共识声明
- 期刊
- American journal of hematology2026 Jul
- 原文标识
- PubMed 42014940 · DOI 10.1002/ajh.70339